MedPath

Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney Cancer

Phase 3
Completed
Conditions
Kidney Cancer
Registration Number
NCT00002737
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Brief Summary

RATIONALE: Interferon alfa may interfere with the growth of the cancer cells and slow the growth of kidney cancer. Isotretinoin may help kidney cancer cells develop into normal cells. It is not yet known whether interferon alfa plus isotretinoin is more effective than interferon alfa alone for kidney cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of interferon alfa with or without isotretinoin in treating patients who have metastatic kidney cancer.

Detailed Description

OBJECTIVES: I. Assess the response rate and response duration of interferon alfa with vs without isotretinoin in patients with bidimensionally measurable progressive metastases from renal cell cancer. II. Assess the toxic effects of these regimens in this patients population. III. Determine the overall survival of this patient population treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center. Patients are randomized to one of two treatment arms. Arm I: Patients receive interferon alfa subcutaneously daily. Arm II: Patients receive interferon alfa as in arm I plus oral isotretinoin daily. Treatment continues for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients are followed until death.

PROJECTED ACCRUAL: A total of 296 patients will be accrued for this study.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
320
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (27)

Onze Lieve Vrouw Ziekenhuis Aalst

🇧🇪

Aalst, Belgium

Algemeen Ziekenhuis Middelheim

🇧🇪

Antwerp, Belgium

Groot Ziekengasthuis 's-Hertogenbosch

🇳🇱

Hertogenbosch, Netherlands

Kantonsspital - Saint Gallen

🇨🇭

Saint Gallen, Switzerland

Universitaetsspital

🇨🇭

Zurich, Switzerland

University Medical Center Nijmegen

🇳🇱

Nijmegen, Netherlands

Beatson Oncology Centre

🇬🇧

Glasgow, Scotland, United Kingdom

Ospedale di Circolo e Fondazione Macchi

🇮🇹

Varese, Italy

Institut Jules Bordet

🇧🇪

Brussels, Belgium

Universitair Ziekenhuis Antwerpen

🇧🇪

Edegem, Belgium

Antoni van Leeuwenhoekhuis

🇳🇱

Amsterdam, Netherlands

Leiden University Medical Center

🇳🇱

Leiden, Netherlands

U.Z. Gasthuisberg

🇧🇪

Leuven, Belgium

Norwegian Radium Hospital

🇳🇴

Oslo, Norway

University Hospital - Rotterdam Dijkzigt

🇳🇱

Rotterdam, Netherlands

Rotterdam Cancer Institute

🇳🇱

Rotterdam, Netherlands

Academisch Medisch Centrum

🇳🇱

Amsterdam, Netherlands

National Institute of Oncology

🇭🇺

Budapest, Hungary

Ratisches Kantons und Regionalspital

🇨🇭

Chur, Switzerland

Marmara University Hospital

🇹🇷

Istanbul, Turkey

Academisch Ziekenhuis Utrecht

🇳🇱

Utrecht, Netherlands

Kantonspital Aarau

🇨🇭

Aarau, Switzerland

Ospedale San Giovanni

🇨🇭

Bellinzona, Switzerland

Russian Academy of Medical Sciences Cancer Research Center

🇷🇺

Moscow, Russian Federation

Centre Hospitalier Universitaire Vaudois

🇨🇭

Lausanne, Switzerland

Inselspital, Bern

🇨🇭

Bern, Switzerland

Bristol Royal Infirmary

🇬🇧

Bristol, England, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath